Lanicemine

Cat. No.:	HY-108235
CAS No.:	153322-05-5
Molecular Formula:	$C_{13}H_{14}N_2$
Molecular Weight:	198.26
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (K_i of 0.56-2.1 μM for NMDA receptor; IC_{50}s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1].
IC_{50} & Target	NMDA receptor[1]
In Vivo	Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1].Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats[1]
Dosage:	3, 10 or 30 mg/kg
Administration:	Intraperitoneal
Result:	Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity.

REFERENCES

[1]. Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA